Seladelpar improves PBC transplant-free survival – EASL 2022 – POSTER
Seladelpar treatment of patients with primary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival
Seladelpar treatment over 2 years resulted in a sustained decrease in GLOBE score for
patients with PBC that is associated with a predicted improvement in transplant-free survival. SEE POSTER.